BridgeBio sells Attruby for transthyretin amyloid cardiomyopathy, a heart disease, and has three oral medicines under FDA review for rare genetic conditions.
Attruby's growing sales support BridgeBio's transition to multiple products. BBP-418, oral infigratinib and encaleret remain under Priority Review, with launch teams ready. Cash of $1.5 billion at September 30, 2026 includes July's $933.9 million preferred financing. Management expects cash plus product and partner collections to fund at least the next 12 months under current plans. Preferred dividends, royalty obligations and convertible debt constrain flexibility. The investment case depends on FDA approvals and commercial execution while Attruby keeps growing.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA approves BBP-418
Does FDA approve BBP-418 for LGMD2I/R9 using the FORTIFY interim results?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Attruby grows as BridgeBio prepares three launches; BBP-418 decision comes first
Three Phase 3 programs with positive data and NDAs under Priority Review; the FDA decisions starting November 2026 are the make-or-break condition
Three Phase 3 wins and one approved ATTR drug; whether two oral-pill NDAs clear FDA in early 2027 determines the next leg
Three late-stage programs heading to FDA decisions; encaleret's May 2027 PDUFA with clean Phase 3 data tests whether BridgeBio can become a multi-franchise rare-disease company
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: Encaleret
Disease areas: Neuromuscular diseases, Neurology and pain, Obesity, diabetes and heart disease, Endocrine and bone diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
3 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.